J Korean Ophthalmol Soc > Volume 56(8); 2015 > Article
Journal of the Korean Ophthalmological Society 2015;56(8):1223-1228.
DOI: https://doi.org/10.3341/jkos.2015.56.8.1223    Published online August 15, 2015.
The Effect of Intravitreal Bevacizumab Injection before Panretinal Photocoagulation in Patients with Clinically Significant Macular Edema.
Chang Zoo Kim, Ki Yup Nam, Seung Uk Lee, Sang Joon Lee
Department of Ophthalmology and Institute of Medicine, Kosin University College of Medicine, Busan, Korea. hhiatus@gmail.com
유의한 황반부종이 있는 비증식당뇨망막병증 환자의 범망막광응고술과 베바시주맙병합치료의 장기효과
김창주⋅남기엽⋅이승욱⋅이상준
고신대학교 의과대학 안과학교실 및 의과학연구소
Received: 29 January 2015   • Revised: 18 March 2015   • Accepted: 1 July 2015
Abstract
PURPOSE
To determine the effect of intravitreal bevacizumab injection before panretinal photocoagulation (PRP) in clinically significant macular edema (CSME) patients. METHODS: A total of 91 eyes (70 patients) having severe nonproliferative diabetic retinopathy with CSME requiring PRP were enrolled in the present study; the medical records were retrospectively reviewed and analyzed. The eyes were divided into the regular PRP group (51 eyes) and PRP with preinjection of bevacizumab (1.25 mg) group (combination group, 40 eyes) and compared. Best corrected visual acuity (BCVA) and central macular thickness (CMT) at pretreatment and 1, 3, 6, and 12 months after PRP was evaluated. RESULTS: BCVA (logarithm of the minimum angle of resolution, Snellen visual acuity in parentheses) at pretreatment and 1, 3, 6, and 12 months after PRP was 0.24 (0.575), 0.27 (0.537), 0.28 (0.525), 0.28 (0.525), and 0.30 (0.501) (p = 0.13, 0.15, 0.56 and 0.79) in the regular PRP group and 0.32 (0.479), 0.25 (0.562), 0.26 (0.549), 0.27 (0.537), and 0.36 (0.436) (p = 0.02, 0.04, 0.02 and 0.13) in the combination group, respectively. CMT (microm) at pretreatment and 1, 3, 6, and 12 months after PRP was 257.66, 285.16, 282.21, 289.65, and 309.85 (p = 0.00, 0.00, 0.00 and 0.00) in the regular PRP group and 349.39, 312.17, 331.15. 353.30, and 333.55 (p = 0.04, 0.94, 0.79 and 0.06) in the combination group, respectively. CONCLUSIONS: Pretreatment of anti-vascular endothelial growth factor injection before PRP affected the decrease of macular thickness for 3 months after PRP and improved visual acuity for 6 months after PRP when compared with PRP alone in patients with CSME.
Key Words: Bevacizumab;Diabetic retinopathy;Macular edema;Panretinal photocoagulation


ABOUT
BROWSE ARTICLES
EDITORIAL POLICY
FOR CONTRIBUTORS
Editorial Office
SKY 1004 Building #701
50-1 Jungnim-ro, Jung-gu, Seoul 04508, Korea
Tel: +82-2-583-6520    Fax: +82-2-583-6521    E-mail: kos08@ophthalmology.org                

Copyright © 2021 by Korean Ophthalmological Society.

Developed in M2PI

Close layer
prev next